Cerus Corporation (Nasdaq: CERS) announced today that it has commenced a registered underwritten public offering of $50.0 million of its common stock. In addition, Cerus expects to grant the underwriter a 30-day option to purchase up to an additional $7.5 million of its common stock. All of the shares to be sold in the offering are to be sold by Cerus.
BTIG, LLC is acting as sole book-running manager for the offering.
A shelf registration statement on Form S-3 (File No. 333-219727) relating to the shares of common stock described above was previously filed by Cerus with the Securities and Exchange Commission ("SEC") and declared effective on January 8, 2018. A preliminary prospectus supplement related to the offering will be filed with the SEC. Prospective investors should read the preliminary prospectus supplement, when available, and the accompanying prospectus and other documents Cerus has filed with the SEC for more complete information about Cerus and the proposed offering. These documents are available at no charge by visiting the SEC's website at http://www.sec.gov. Alternatively, copies of the preliminary prospectus supplement, when available, and the accompanying prospectus may be obtained by contacting BTIG, LLC at 65 East 55th Street, New York, NY, 10022, by email at email@example.com or by telephone at (212) 593-7555.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply. Based in Concord, California, Cerus develops and markets the INTERCEPT Blood System. Cerus currently markets and sells the INTERCEPT Blood System in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world.
Forward Looking Statements
This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to the completion, timing and size of Cerus’ public offering. These forward-looking statements are based upon Cerus’ current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks related to completion of the proposed public offering on the anticipated terms, if at all, market conditions and the satisfaction of customary closing conditions related to the public offering, risks related to the application of the net proceeds from the public offering, risks associated with the uncertain research and product development process, and other risks detailed in Cerus' filings with the SEC, including in Cerus' quarterly report on Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on October 30, 2019 and in the preliminary prospectus supplement related to the public offering to be filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise